Skip to main content
Delfa

← All assets

Progesterone

1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

1

Ongoing

0

Recruiting

0

Completed

1

Sites

1

Countries

1

Endpoints

0

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. ClinicalTrials.gov reports no endpoints for this asset’s linked trials. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1

Trials by status

Completed
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

No endpoints are reported by ClinicalTrials.gov for these trials.

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 0 of 0 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

No normalized metric codes are available for this asset.

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

1 of 1

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00006399Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

Donepezil, estrogen, Progesterone

Alzheimer’s disease

Age 45-85Ph 2Completed1Mar 20042

Showing 1-1 of 1 trials